Hutchison China MediTech Limited announced with effect from February 1, 2017, Mr. Paul Rutherford Carter has been appointed as Senior Independent Non-Executive Director and member of the Audit Committee, Remuneration Committee and Technical Committee of Chi-Med; and Mr. Shigeru Endo tendered his resignation as Non-executive Director and Mr. Christopher Nash tendered his resignation as Senior Independent Non-executive Director and member of Audit Committee and Remuneration Committee effective on the same date. Mr. Carter is currently a director of Alder Biopharmaceuticals Inc. He was previously a director of Gilead Sciences Ltd, Gilead Sciences International Ltd. and Gilead Sciences Europe Ltd. within the past five years. From 2006 to 2016, Mr. Carter served in various senior executive roles at Gilead Sciences Inc., with the last position as Executive Vice President, Commercial Operations. In this role Mr. Carter headed the worldwide commercial organization responsible for the launch and commercialization of all of Gilead¡¦s products. Prior to joining Gilead, he spent 14 years with GlaxoSmithKline PLC (GSK) and its group companies, with the last position as a Regional Head of the International business in Asia.